Cannabinoid-Based Drugs Seek New High, Part II
Developers Anticipate Additional Approvals after FDA Nod for Epidiolex
Single-Cell Cloning Remains a Challenge
Evolving Technologies Help Make It Easier to Meet Regulatory Requirements
Pushing the Right Buttons
Improving Efficacy of Therapeutic DNA Vectors
Organs-on-Chips Take Flight
Initiative to Use Technology Aboard International Space Station Set to Begin
James Vasta Ph.D.
James Vasta, Ph.D., is a research scientist at Promega.